A helicase-primase drug candidate with sufficient target tissue exposure affects latent neural herpes simplex virus infections

Although current treatments for herpes simplex viruses (HSV) have improved considerably over the past few decades, they remain unable to treat latent infection. Here, Gege et al. developed and tested IM-250, a helicase-primase inhibitor, as a means of treating both active and latent HSV infection. IM-250 showed favorable pharmacokinetics and safety and demonstrated in vitro anti-HSV activity. To…

Read the full article here

Related Articles